Who are Tenofovir (TDF)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 3TC, TDF treatment, lamivudine or entecavir, Tenofovir alafenamide(TAF), TAF based regimen (TBR).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenofovir-tdf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tenofovir (TDF) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenofovir (TDF) (Tenofovir (TDF)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor (NtRTI). Area: Virology/Infectious Disease.

marketed Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase; Hepatitis B polymerase Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tenofovir (TDF) (Tenofovir (TDF)) — French National Agency for Research on AIDS and Viral Hepatitis. Tenofovir is a nucleotide reverse transcriptase inhibitor that blocks HIV and hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tenofovir (TDF) TARGET	Tenofovir (TDF)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase; Hepatitis B polymerase
3TC	3TC	Avexa	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; hepatitis B polymerase
TDF treatment	TDF treatment	New Discovery LLC	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	Viral reverse transcriptase
lamivudine or entecavir	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase
Tenofovir alafenamide(TAF)	Tenofovir alafenamide(TAF)	Humanity and Health Research Centre	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase
TAF based regimen (TBR)	TAF based regimen (TBR)	ViiV Healthcare	phase 3	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor (NtRTI) class)

French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
Humanity and Health Research Centre · 1 drug in this class
New Discovery LLC · 1 drug in this class
ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenofovir (TDF) — Competitive Intelligence Brief. https://druglandscape.com/ci/tenofovir-tdf. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing